Diffuse Peritoneal Carcinomatosis of Prostate Cancer Unveiled by [89Zr]Zr-PSMA-617 PET/CT

Clin Nucl Med. 2025 Feb 1;50(2):191-192. doi: 10.1097/RLU.0000000000005604.

Abstract

We report an interesting case of a 64-year-old man with a history of radical prostatectomy for prostate cancer. The patient presented with steady increasing prostate-specific antigen levels, but with negative findings on previous multiple conventional prostate-specific membrane antigen (PSMA) PET/CT (with [68Ga]Ga-PSMA-11) and [18F]FDG PET/CT. A recently introduced PSMA tracer using long-lived 89Zr (half-life 3.3 days), [89Zr]Zr-PSMA-617, was administered in attempt to localize potential local recurrence or metastasis. [89Zr]Zr-PSMA-617 PET/CT clearly revealed diffuse peritoneal carcinomatosis and local recurrence of the prostate cancer, which were unidentified on previous conventional PET/CT scans. This case highly demonstrates the potential of PET imaging with the novel PSMA tracer [89Zr]Zr-PSMA-617.

Publication types

  • Case Reports

MeSH terms

  • Dipeptides*
  • Heterocyclic Compounds, 1-Ring
  • Humans
  • Male
  • Middle Aged
  • Peritoneal Neoplasms* / diagnostic imaging
  • Peritoneal Neoplasms* / secondary
  • Positron Emission Tomography Computed Tomography*
  • Prostate-Specific Antigen
  • Prostatic Neoplasms* / diagnostic imaging
  • Prostatic Neoplasms* / pathology
  • Radioisotopes
  • Zirconium*

Substances

  • Dipeptides
  • PSMA-617
  • Zirconium
  • Heterocyclic Compounds, 1-Ring
  • Zirconium-89
  • Radioisotopes
  • Prostate-Specific Antigen